Kamada Ltd. (KMDA) Receives $9.00 Average PT from Brokerages

Kamada Ltd. (NASDAQ:KMDA) has been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.00.

Several brokerages have recently issued reports on KMDA. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Friday, August 10th. BidaskClub upgraded shares of Kamada from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Finally, HC Wainwright set a $11.00 price target on shares of Kamada and gave the stock a “buy” rating in a report on Wednesday, August 8th.

KMDA traded up $0.04 during trading on Thursday, hitting $5.22. 2,806 shares of the stock traded hands, compared to its average volume of 7,002. The company has a market cap of $210.18 million, a P/E ratio of 19.33 and a beta of 1.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 3.31. Kamada has a twelve month low of $4.26 and a twelve month high of $6.45.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Monday, November 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.05). The company had revenue of $14.98 million for the quarter, compared to analyst estimates of $25.99 million. Kamada had a return on equity of 11.70% and a net margin of 10.60%. On average, analysts expect that Kamada will post 0.27 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in KMDA. Jane Street Group LLC acquired a new position in shares of Kamada during the second quarter worth $146,000. Macquarie Group Ltd. increased its holdings in shares of Kamada by 71.7% during the second quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock worth $247,000 after buying an additional 19,851 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Kamada by 14.8% during the second quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock worth $616,000 after buying an additional 15,440 shares in the last quarter. Worth Venture Partners LLC increased its holdings in shares of Kamada by 203.4% during the third quarter. Worth Venture Partners LLC now owns 155,719 shares of the biotechnology company’s stock worth $963,000 after buying an additional 104,397 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Kamada by 157.8% during the second quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock worth $1,507,000 after buying an additional 179,237 shares in the last quarter. Institutional investors own 13.17% of the company’s stock.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).

Further Reading: Cash Flow Analysis in Stock Selection

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit